Many groups are developing anti-AML CAR designs with targets including CD33, folate receptor β (FRβ), CD123, C-type lectin molecule 1 (CLL1), PR1/HLA-A2, CD70, T cell immunoglobulin mucin-3 (TIM-3), CD13, and CD93. Here, HAVCR2 is linked to acute myeloid leukemia.